Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombivax-HB Injection Site Comparison in Elderly
NCT04162223Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Mar 2000
- Primary completion
- May 2003
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Recombivax HB in hepatitis B (HBV) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Hepatitis B surface antibody titers at 2 years and Cell-mediated immune responses at 2 years. Started Mar 2000; status: completed.
02
Drugs
Recombivax HB
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04162223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162223.